دورية أكاديمية
Effect of Gum Arabic on plaque-induced gingivitis: A randomised controlled trial.
العنوان: | Effect of Gum Arabic on plaque-induced gingivitis: A randomised controlled trial. |
---|---|
المؤلفون: | Gafar AM; Sudan Medical Specialisation Board, Khartoum, Sudan., Ramadan AM; Ibn Sina National College, Saudi Arabia., ElSaid NA; Toronto, Canada., Nurelhuda NM; Faculty of Dentistry, University of Khartoum, Sudan. |
المصدر: | The Saudi dental journal [Saudi Dent J] 2022 Sep; Vol. 34 (6), pp. 494-502. Date of Electronic Publication: 2022 Jun 13. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Saudi Dental Society Country of Publication: Saudi Arabia NLM ID: 9313603 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1013-9052 (Print) Linking ISSN: 10139052 NLM ISO Abbreviation: Saudi Dent J Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Riyadh : Saudi Dental Society, 1989- |
مستخلص: | New approaches to treating periodontal diseases aim to balance sustaining the natural oral microbiota and modifying the host immune response. Gum Arabic (GA) is a natural polysaccharide rich in prebiotics.The aim of this study was to assess the effect of GA on clinical (Plaque Index (PI), Gingival Index (GI)) and immunological (Gingival Crevicular Fluid Interleukin 1 Beta (GCF IL-1 β)) parameters in patients with plaque-induced gingivitis. Materials and Methods: This placebo-controlled, double-blinded randomised clinical trial was conducted at the Department of Periodontology at Khartoum Dental Teaching Hospital, Khartoum, Sudan, from July to October 2016. Patients diagnosed with plaque-induced gingivitis meeting the study eligibility criteria were enrolled. At baseline, PI, GI and GCF IL-1β were measured. Patients received full-mouth scaling and were randomly assigned to receive either GA powder (intervention group) or Microcrystalline cellulose powder (placebo group). The patients were instructed to apply the treatment twice a day throughout the study. The PI, GI and GCF IL-1β were reassessed after 30 and 60 days. Results: A total of 60 patients were enrolled (30 in each group). Compared to the placebo group, the intervention group showed a statistically significant reduction in GI scores after 30 days and improved PI scores at 30 and 60 days. Between baseline and 60 days, patients who received GA exhibited a significant reduction in GCF IL-1β levels compared to the placebo group. Conclusion: GA was found to be effective in controlling plaque and gingivitis. Clinical Trial Registration. ISRCTN registry ISRCTN14209449. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.) |
References: | J Biochem Mol Toxicol. 2003;17(3):146-53. (PMID: 12815610) J Dent Res. 1993 Aug;72(8):1194-7. (PMID: 8360362) Aust Dent J. 2012 Sep;57(3):312-8. (PMID: 22924354) J Clin Periodontol. 2002 Jan;29(1):48-53. (PMID: 11846849) Saudi Dent J. 2018 Jan;30(1):53-62. (PMID: 30166872) Food Chem Toxicol. 2009 Jan;47(1):1-8. (PMID: 18672018) Front Biosci. 2008 Jan 01;13:966-84. (PMID: 17981604) J Indian Soc Periodontol. 2008 Sep;12(3):79-83. (PMID: 20142950) J Clin Periodontol. 2012 Mar;39(3):295-302. (PMID: 22126282) J Periodontol (1930). 1965 May-Jun;36:177-87. (PMID: 14296927) J Oral Microbiol. 2009 May 01;1:. (PMID: 21523212) Chin J Dent Res. 2012;15(1):49-53. (PMID: 22866283) J Periodontal Res. 1993 Jul;28(4):241-7. (PMID: 8101565) J Clin Periodontol. 1993 Apr;20(4):238-43. (PMID: 8473532) Aust Dent J. 2010 Mar;55(1):65-9. (PMID: 20415914) J Appl Oral Sci. 2009 Sep-Oct;17(5):404-7. (PMID: 19936516) Acta Odontol Scand. 1963 Dec;21:533-51. (PMID: 14121956) J Clin Periodontol. 2011 Mar;38 Suppl 11:159-77. (PMID: 21323712) Front Immunol. 2020 Jan 31;10:3119. (PMID: 32082302) Clin Microbiol Rev. 2003 Oct;16(4):658-72. (PMID: 14557292) J Periodontol. 1984 Dec;55(12):684-8. (PMID: 6394735) Inflamm Res. 2009 May;58(5):277-83. (PMID: 19184351) mSphere. 2021 Aug 25;6(4):e0016221. (PMID: 34287005) Acta Odontol Scand. 2003 Aug;61(4):193-6. (PMID: 14582585) Oxid Med Cell Longev. 2009 Sep-Oct;2(4):207-13. (PMID: 20716906) J Clin Periodontol. 2016 Sep;43(9):727-45. (PMID: 27027257) J Clin Periodontol. 2017 May;44(5):456-462. (PMID: 28419559) Ren Fail. 2004 Jan;26(1):1-3. (PMID: 15083914) Oral Dis. 2000 May;6(3):138-51. (PMID: 10822357) Br J Nutr. 2008 Dec;100(6):1269-75. (PMID: 18466655) Afr J Tradit Complement Altern Med. 2009 May 07;6(3):228-32. (PMID: 20448847) J Nutr. 1995 Jun;125(6):1401-12. (PMID: 7782892) Acta Odontol Scand. 1964 Feb;22:121-35. (PMID: 14158464) Int J Oral Sci. 2020 Jan 2;12(1):2. (PMID: 31900383) Pharmacol Res. 2003 Dec;48(6):631-5. (PMID: 14527829) Drug Metab Rev. 2004 Oct;36(3-4):805-22. (PMID: 15554248) J Biochem Mol Toxicol. 2002;16(5):254-9. (PMID: 12439867) J Clin Periodontol. 1991 Jan;18(1):75-7. (PMID: 2045522) Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1427-1436. (PMID: 32157347) Int J Rheumatol. 2018 Jul 05;2018:4197537. (PMID: 30112005) BMC Oral Health. 2012 Feb 24;12:5. (PMID: 22364514) |
فهرسة مساهمة: | Keywords: Antimicrobial; Chemical plaque control; Clinical trial; Gingivitis; Gum Arabic |
تواريخ الأحداث: | Date Created: 20220912 Latest Revision: 20220913 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9453537 |
DOI: | 10.1016/j.sdentj.2022.06.002 |
PMID: | 36092515 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1013-9052 |
---|---|
DOI: | 10.1016/j.sdentj.2022.06.002 |